Literature DB >> 1068742

Philadelphia chromosome in acute leukemia: case report.

L M Walker, J D Hardy.   

Abstract

A case report of serial chromosome studies on a child presumed to have acute lymphoblastic leukemia (ALL) is presented. Hematologic remission was achieved after 3 weeks and maintained until death 63 weeks later. The classic Philadelphia chromosome translocation was found, both at diagnosis and throughout the course of the disease, in a proportion of cells from PHA-stimulated blood cultures. The finding is related to other reports of Philadelphia-positive clones in ALL, as well as those in chronic myeloid leukemia and its acute transformation, and other myeloproliferative disorders. The origin of the Philadelphia chromosome in this case is considered in the light of current stem cell theory, and its relevance to lymphocytic neoplasia is discussed. We believe that the finding of a Ph1-positive clone in a cell line morphologically indistinguishable from normal lymphocytes in a case of acute leukemia is unique.

Entities:  

Mesh:

Year:  1976        PMID: 1068742     DOI: 10.1002/1097-0142(197610)38:4<1619::aid-cncr2820380429>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Familial leukemia: Ph1 positive acute lymphoid leukemia of a mother and her infant.

Authors:  E Oláh; V Stenszky; A Kiss; I Kovács; E Balogh; L Karmazsin
Journal:  Blut       Date:  1981-10

2.  Chromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia.

Authors:  E L Prigogina; E W Fleischman; M A Volkova; M A Frenkel
Journal:  Hum Genet       Date:  1978-03-17       Impact factor: 4.132

3.  New complex Ph' translocation t (10; 14; 22) in bone marrow cells and in PHA-stimulated peripheral blood cultures in chronic myelocytic leukaemia.

Authors:  F Shabtai; U Gafter; S Weiss; M Djaldetti; I Halbrecht
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.